Skip to main content
Clinical Trials/NCT00158535
NCT00158535TerminatedPhase 2

Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection ANRS HC08 Thevic

French National Agency for Research on AIDS and Viral Hepatitis2 sites in 1 country15 target enrollmentStarted: June 1, 2002Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Terminated
Sponsor
Enrollment
15
Locations
2
Primary Endpoint
Feasibility of liver transplantation in patients with HCV-HIV coinfection: survival at one and two years.

Study Overview

Brief Summary

To show the feasibility of liver transplantation in HCV-HIV coinfected patients. To study the two-year survival after transplantation, the interaction between HCV and HIV after transplantation, the influence of HIV on HCV recurrence after transplantation, the interaction between immunosuppressive and antiretroviral drugs in particular anti-proteases, immunological follow-up and quality of life of these patients

Detailed Description

Until recently, HIV infection was considered as a contraindication for liver transplantation. A dramatic improvement in survival of HIV patients have been observed since the advent of new antiviral treatments against HIV including antiproteases. However an important proportion of patients with HCV-HIV coinfection are suffering from life-threatening liver disease due to HCV infection. Liver transplantation may be considered in this particular group of patients.

The ideal timing for the indication of liver transplantation during HIV disease and during the course of HCV liver disease needs to be defined. Liver transplantation in this particular group of patients raised several questions : a) the role of HIV infection on prevalence and severity of HCV recurrence after transplantation ; b) the role of liver transplantation and immunosuppression on HIV disease ; c) drug interactions between immunosuppressive agents and antiproteases ; d) immunological follow-up and quality of life of these patients.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 69 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Coinfection HIV-HVC
  • Indication of liver transplantation for severe hepatopathy with life threatening:repetitive ascitis or infection of ascitis or icterus or decreased of prothrombin index under 50 percent or digestive haemorrhage by portal hypertension uncontrolled

Exclusion Criteria

  • Toxicomania
  • Alcohol consumer (over 30g per day)
  • AgHBs positive
  • hepatocarcinoma over 5 cm or 3 nodules
  • CD4 below 200/mm3
  • Viral load below 400 cp
  • HIV stade C

Outcomes

Primary Outcomes

Feasibility of liver transplantation in patients with HCV-HIV coinfection: survival at one and two years.

Secondary Outcomes

  • Graft survival
  • Unexpected infections or neoplasia
  • Toxicity of antiretroviral and immunosuppressive treatments
  • Replicative kinetics of HIV and HVC after transplantation in blood and liver
  • Immune status of HIV and HVC
  • Quality of life

Investigators

Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Sponsor Class
Other Gov

Study Sites (2)

Loading locations...

Similar Trials